SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
PURSUANT TO SECTION 13 OR 15(D) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report: January 4, 2013
BioCryst Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in Charter)
(State or other jurisdiction
4505 Emperor Blvd., Suite 200
Durham, North Carolina 27703
(Address of Principal Executive Office)
(Registrants telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):
|¨||Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
|¨||Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
|¨||Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 210.14d-2(b))|
|¨||Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))|
|Item 5.02||Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.|
On January 4, 2013, Robert S. Lowrey, the Controller and Principal Accounting Officer of BioCryst Pharmaceuticals, Inc. (the Company), tendered his resignation from employment with the Company, effective January 25, 2013.
Beginning January 26, 2013, Mr. Thomas Staab, who has been the Companys Chief Financial Officer since July 1, 2011, will serve as the Companys Chief Financial and Principal Accounting Officer.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|Dated: January 7, 2013||BioCryst Pharmaceuticals, Inc.|
|General Counsel, Corporate Secretary|